Search

Your search keyword '"Wagner, John E."' showing total 860 results
Start Over Author "Wagner, John E." Publication Type Academic Journals

Refine your results

more »

more »

more »

more »

more »
860 results on '"Wagner, John E."'

2. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice

Author

Saha, Asim, Palchaudhuri, Rahul, Lanieri, Leanne, Hyzy, Sharon, Riddle, Megan J., Panthera, Jamie, Eide, Cindy R., Tolar, Jakub, Panoskaltsis-Mortari, Angela, Gorfinkel, Lev, Tkachev, Victor, Gerdemann, Ulrike, Alvarez-Calderon, Francesca, Palato, Elisa Rojas, MacMillan, Margaret L., Wagner, John E., Kean, Leslie S., Osborn, Mark J., Kiem, Hans-Peter, Scadden, David T., Olson, Lisa M., and Blazar, Bruce R.

Published
2024
Full Text
View/download PDF

5. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer

Author

Webster, Andrew L. H., Sanders, Mathijs A., Patel, Krupa, Dietrich, Ralf, Noonan, Raymond J., Lach, Francis P., White, Ryan R., Goldfarb, Audrey, Hadi, Kevin, Edwards, Matthew M., Donovan, Frank X., Hoogenboezem, Remco M., Jung, Moonjung, Sridhar, Sunandini, Wiley, Tom F., Fedrigo, Olivier, Tian, Huasong, Rosiene, Joel, Heineman, Thomas, Kennedy, Jennifer A., Bean, Lorenzo, Rosti, Rasim O., Tryon, Rebecca, Gonzalez, Ashlyn-Maree, Rosenberg, Allana, Luo, Ji-Dung, Carroll, Thomas S., Shroff, Sanjana, Beaumont, Michael, Velleuer, Eunike, Rastatter, Jeff C., Wells, Susanne I., Surrallés, Jordi, Bagby, Grover, MacMillan, Margaret L., Wagner, John E., Cancio, Maria, Boulad, Farid, Scognamiglio, Theresa, Vaughan, Roger, Beaumont, Kristin G., Koren, Amnon, Imielinski, Marcin, Chandrasekharappa, Settara C., Auerbach, Arleen D., Singh, Bhuvanesh, Kutler, David I., Campbell, Peter J., and Smogorzewska, Agata

Published
2022
Full Text
View/download PDF

6. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Author

Ramos, Teresa L., Bolivar-Wagers, Sara, Jin, Sujeong, Thangavelu, Govindarajan, Simonetta, Federico, Lin, Po-Yu, Hirai, Toshihito, Saha, Asim, Koehn, Brent, Su, Leon L., Picton, Lora K., Baker, Jeanette, Lohmeyer, Juliane K., Riddle, Megan, Eide, Cindy, Tolar, Jakub, Panoskaltsis-Mortari, Angela, Wagner, John E., Garcia, K. Christopher, Negrin, Robert S., and Blazar, Bruce R.

Published
2023
Full Text
View/download PDF

7. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study

Author

Eapen, Mary, Brazauskas, Ruta, Walters, Mark C, Bernaudin, Françoise, Bo-Subait, Khalid, Fitzhugh, Courtney D, Hankins, Jane S, Kanter, Julie, Meerpohl, Joerg J, Bolaños-Meade, Javier, Panepinto, Julie A, Rondelli, Damiano, Shenoy, Shalini, Williamson, Joi, Woolford, Teonna L, Gluckman, Eliane, Wagner, John E, and Tisdale, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Hematology, Regenerative Medicine, Stem Cell Research, Rare Diseases, Orphan Drug, Clinical Research, Adolescent, Adult, Anemia, Sickle Cell, Blood Donors, Bone Marrow Transplantation, Child, Female, Fetal Blood, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Progression-Free Survival, Proportional Hazards Models, Retrospective Studies, Survival Rate, Transplantation, Homologous, Young Adult, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

BackgroundDonors other than matched siblings and low-intensity conditioning regimens are increasingly used in haematopoietic stem cell transplantation. We aimed to compare the relative risk of donor type and conditioning regimen intensity on the transplantation outcomes of in patients with sickle cell disease.MethodsFor this retrospective cohort study, we collected data from 90 US centres reported to the Center for International Blood and Marrow Transplant Research. Eligible patients were younger than 50 years, had genetically confirmed sickle cell disease (Hb SS) or sickle beta thalassemia (Hb Sβ), and underwent allogeneic haematopoietic cell transplantation between Jan 15, 2008, and Dec 28, 2017. We considered transplants from donor-recipient pairs matched at the allele-level (HLA-A, HLA-B, HLA-C, and HLA-DRB1), including HLA-matched sibling donors, haploidentical related donors, matched unrelated donors, or mismatched unrelated donors. The main outcome was event-free survival. The effect of donor type, conditioning regimen intensity (myeloablative, non-myeloablative, and reduced-intensity regimens), age (≤12 or 13-49 years), sex, performance score, comorbidity index, recipient cytomegalovirus serostatus, graft type (bone marrow, peripheral blood, or umbilical cord blood), and transplantation period (2008-12 and 2013-17) on outcomes was studied using Cox regression models.FindingsOf 996 patients with sickle cell disease and who underwent transplantation in 2008-17, 910 (91%) were included (558 [61%] patients had HLA-matched sibling donors, 137 [15%] haploidentical related donors, 111 [12%] matched unrelated donors, and 104 [11%] mismatched unrelated donors). The median follow-up was 36 months (IQR 18-60) after transplantation from HLA-matched siblings, 25 months (12-48) after transplantation from haploidentical related donors, 37 months (23-60) after transplantation from HLA-matched unrelated donors, and 47 months (24-72) after transplantation from mismatched unrelated donors. Event-free survival was worse in recipients aged 13 years or older than in those younger than 13 years (hazard ratio 1·74, 95% CI 1·24-2·45; p=0·0014) and in those who received a transplant from haploidentical related donors (5·30, 3·17-8·86; p

Published
2019

8. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Author

Saha, Asim, Hyzy, Sharon, Lamothe, Tahirih, Hammond, Katelyn, Clark, Nicholas, Lanieri, Leanne, Bhattarai, Prashant, Palchaudhuri, Rahul, Gillard, Geoffrey O., Proctor, Jennifer, Riddle, Megan J., Panoskaltsis-Mortari, Angela, MacMillan, Margaret L., Wagner, John E., Kiem, Hans-Peter, Olson, Lisa M., and Blazar, Bruce R.

Published
2022
Full Text
View/download PDF

9. Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

Author

Rothenberger, Meghan, Wagner, John E, Haase, Ashley, Richman, Douglas, Grzywacz, Bartosz, Strain, Matthew, Lada, Steven, Estes, Jacob, Fletcher, Courtney V, Podany, Anthony T, Anderson, Jodi, Schmidt, Thomas, Wietgrefe, Steve, Schacker, Timothy, and Verneris, Michael R

Subjects
CCR5∆32, HIV cure, HIV reservoirs, allogeneic bone marrow transplantation, CCR5 Delta 32, Transplantation, Pediatric, HIV/AIDS, Hematology, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Cancer, Regenerative Medicine, Infection
Abstract

BackgroundAllogeneic hematopoietic cell transplantation (allo-HCT) in a CCR5∆32 homozygous donor resulted in HIV cure. Understanding how allo-HCT impacts the HIV reservoir will inform cure strategies.MethodsA 12-year-old with perinatally acquired, CCR5-tropic HIV and acute lymphoblastic leukemia underwent myeloablative conditioning and umbilical cord blood (UCB) transplantation from a CCR5∆32 homozygous donor. Peripheral blood mononuclear cells (PBMCs) and the rectum were sampled pre- and post-transplant. The brain, lung, lymph node (LN), stomach, duodenum, ileum, and colon were sampled 73 days after transplantation (day +73), when the patient died from graft-vs-host disease. Droplet digital polymerase chain reaction (ddPCR) and in situ hybridization (ISH) were used detect the HIV reservoir in tissues. CCR5 and CD3 expression in the LN was assessed using immunohistochemistry (IHC).ResultsHIV DNA (vDNA) was detected in PBMCs by ddPCR pretransplant but not post-transplant. vDNA was detected by ISH in the rectum at days -8 and +22, and in the LN, colon, lung, and brain day +73. vDNA was also detected in the lung by ddPCR. IHC revealed CCR5+CD3+ cells in the LN postmortem.ConclusionsHIV was detected in multiple tissues 73 days after CCR5∆32 homozygous UCB allo-HCT despite myeloablative conditioning and complete donor marrow engraftment. These results highlight the importance of analyzing tissue during HIV cure interventions and inform the choice of assay used to detect HIV in tissue reservoirs.

Published
2018

13. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

18. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

Author

Jurdi, Najla El, Hoover, Alex, O'Leary, Daniel, Cao, Qing, Gupta, Ashish, Ebens, Christen, Maakaron, Joseph E., Betts, Brian C., Rashidi, Armin, Juckett, Mark B., Lund, Troy, Bachanova, Veronika, MacMillan, Margaret L, Miller, Jeffrey S., Orchard, Paul J., Wagner, John E., Vercellotti, Gregory, Weisdorf, Daniel J., Dusenbery, Kathryn, Terezakis, Stephanie, and Holtan, Shernan G.

Published
2023
Full Text
View/download PDF

19. Guidelines for Cord Blood Unit Selection

Author

Politikos, Ioannis, Davis, Eric, Nhaissi, Melissa, Wagner, John E., Brunstein, Claudio G., Cohen, Sandra, Shpall, Elizabeth J., Milano, Filippo, Scaradavou, Andromachi, and Barker, Juliet N.

Published
2020
Full Text
View/download PDF

20. Development of specific growth charts for children with Fanconi anemia.

Author

Barbus, Crystal, Rayannavar, Arpana, Miller, Bradley S., Jenkins, Mica J., Addo, O. Yaw, Rayes, Ahmad, Ahrweiler, Natasha, Olson, Alisha, Pohlkamp, Zachary, Wagner, John E., and MacMillan, Margaret L.

Abstract

Patients with Fanconi anemia (FA) are often perceived to have poor growth when general population growth curves are utilized. We hypothesize that FA patients have unique growth and aimed to create FA‐specific growth charts. Height and weight data from ages 0 to 20 years were extracted from medical records of patients treated at the Fanconi Anemia Comprehensive Care Clinic at the University of Minnesota. Height, weight, and BMI growth curves were generated and fitted to reference percentiles using the Lambda‐Mu‐Sigma method. FA‐specific percentiles were compared to WHO standards for ages 0–2 and CDC references for ages 2–20. In FA males, the 50th height‐ and weight‐for‐age percentiles overlap with the 3rd reference percentile. In FA females, only the 50th height‐for‐age percentile overlaps with the 3rd reference percentile. For weight, FA females show progressive growth failure between 6 and 24 months followed by stabilization around the 50th percentile. The FA BMI‐for‐age percentiles show similar patterns to the weight‐for‐age percentiles but have different timing of onset of adiposity rebound and broader variability in females. Growth in FA patients follows a different trajectory than available normative curves. FA‐specific growth charts may be useful to better guide accurate growth expectations, evaluations, and treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease

Author

Holtan, Shernan G., Hoeschen, Andrea, Cao, Qing, Ustun, Celalettin, Betts, Brian C., Jurdi, Najla El, Maakaron, Joseph, Rashidi, Armin, Miller, Jeffrey S., Wagner, John E., Blazar, Bruce R., Jacobson, Pamala A., Panoskaltsis-Mortari, Angela, Weisdorf, Daniel J., and MacMillan, Margaret L.

Published
2023
Full Text
View/download PDF

24. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination

Author

Wang, Anderson T, Kim, Taeho, Wagner, John E, Conti, Brooke A, Lach, Francis P, Huang, Athena L, Molina, Henrik, Sanborn, Erica M, Zierhut, Heather, Cornes, Belinda K, Abhyankar, Avinash, Sougnez, Carrie, Gabriel, Stacey B, Auerbach, Arleen D, Kowalczykowski, Stephen C, and Smogorzewska, Agata

Subjects
Biological Sciences, Genetics, Hematology, Generic health relevance, Cell Survival, Cross-Linking Reagents, DNA, DNA Helicases, DNA Repair, Exodeoxyribonucleases, Fanconi Anemia, Female, Genomic Instability, HEK293 Cells, Heterozygote, Humans, Infant, Mutation, Rad51 Recombinase, RecQ Helicases, Replication Protein A, Werner Syndrome Helicase, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Repair of DNA interstrand crosslinks requires action of multiple DNA repair pathways, including homologous recombination. Here, we report a de novo heterozygous T131P mutation in RAD51/FANCR, the key recombinase essential for homologous recombination, in a patient with Fanconi anemia-like phenotype. In vitro, RAD51-T131P displays DNA-independent ATPase activity, no DNA pairing capacity, and a co-dominant-negative effect on RAD51 recombinase function. However, the patient cells are homologous recombination proficient due to the low ratio of mutant to wild-type RAD51 in cells. Instead, patient cells are sensitive to crosslinking agents and display hyperphosphorylation of Replication Protein A due to increased activity of DNA2 and WRN at the DNA interstrand crosslinks. Thus, proper RAD51 function is important during DNA interstrand crosslink repair outside of homologous recombination. Our study provides a molecular basis for how RAD51 and its associated factors may operate in a homologous recombination-independent manner to maintain genomic integrity.

Published
2015

25. Bone Mineral Density in Children with Fanconi Anemia after Hematopoietic Cell Transplantation

Author

Petryk, Anna, Polgreen, Lynda E, Barnum, Jessie L, Zhang, Lei, Hodges, James S, Baker, K Scott, Wagner, John E, Steinberger, Julia, and MacMillan, Margaret L

Subjects
Pediatric, Osteoporosis, Rare Diseases, Hematology, Pediatric Cancer, Clinical Research, Cancer, Transplantation, 2.1 Biological and endogenous factors, Aetiology, Musculoskeletal, Adolescent, Adult, Allografts, Bone Density, Child, Cross-Sectional Studies, Fanconi Anemia, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Dual energy x-ray absorptiometry scan, Bone mineral density, Bone marrow transplantation, Fanconi anemia, Children, Clinical Sciences, Immunology
Abstract

Fanconi anemia (FA) is an inherited DNA repair disorder associated with short stature and bone marrow failure, usually requiring hematopoietic cell transplantation (HCT). Although low bone mineral density (BMD) has been reported in leukemia patients after HCT, little is known about BMD in FA children after HCT (FA HCT). This study's goals were to compare BMD in FA HCT to BMD in healthy controls and in children who received HCT for hematologic malignancy (cancer HCT), and to test for associations between BMD and risk factors for bone loss. This cross-sectional study included 20 FA HCT, 13 cancer HCT, and 90 healthy controls, age-matched and

Published
2015

28. One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

Author

Wagner, John E, Eapen, Mary, Carter, Shelly, Wang, Yanli, Schultz, Kirk R, Wall, Donna A, Bunin, Nancy, Delaney, Colleen, Haut, Paul, Margolis, David, Peres, Edward, Verneris, Michael R, Walters, Mark, Horowitz, Mary M, and Kurtzberg, Joanne

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Hematology, Stem Cell Research - Nonembryonic - Human, Cancer, Stem Cell Research, Prevention, Clinical Research, Regenerative Medicine, Transplantation, Stem Cell Research - Umbilical Cord Blood/ Placenta, Clinical Trials and Supportive Activities, Rare Diseases, Adolescent, Child, Child, Preschool, Cord Blood Stem Cell Transplantation, Disease-Free Survival, Female, Graft vs Host Disease, Hematologic Neoplasms, Histocompatibility Testing, Humans, Immunotherapy, Infant, Male, Survival Rate, Transplantation Conditioning, Young Adult, Blood and Marrow Transplant Clinical Trials Network, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundUmbilical-cord blood has been used as the source of hematopoietic stem cells in an estimated 30,000 transplants. The limited number of hematopoietic cells in a single cord-blood unit prevents its use in recipients with larger body mass and results in delayed hematopoietic recovery and higher mortality. Therefore, we hypothesized that the greater numbers of hematopoietic cells in two units of cord blood would be associated with improved outcomes after transplantation.MethodsBetween December 1, 2006, and February 24, 2012, a total of 224 patients 1 to 21 years of age with hematologic cancer were randomly assigned to undergo double-unit (111 patients) or single-unit (113 patients) cord-blood transplantation after a uniform myeloablative conditioning regimen and immunoprophylaxis for graft-versus-host disease (GVHD). The primary end point was 1-year overall survival.ResultsTreatment groups were matched for age, sex, self-reported race (white vs. nonwhite), performance status, degree of donor-recipient HLA matching, and disease type and status at transplantation. The 1-year overall survival rate was 65% (95% confidence interval [CI], 56 to 74) and 73% (95% CI, 63 to 80) among recipients of double and single cord-blood units, respectively (P=0.17). Similar outcomes in the two groups were also observed with respect to the rates of disease-free survival, neutrophil recovery, transplantation-related death, relapse, infections, immunologic reconstitution, and grade II-IV acute GVHD. However, improved platelet recovery and lower incidences of grade III and IV acute and extensive chronic GVHD were observed among recipients of a single cord-blood unit.ConclusionsWe found that among children and adolescents with hematologic cancer, survival rates were similar after single-unit and double-unit cord-blood transplantation; however, a single-unit cord-blood transplant was associated with better platelet recovery and a lower risk of GVHD. (Funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute; ClinicalTrials.gov number, NCT00412360.).

Published
2014

29. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Author

Romee, Rizwan, Cooley, Sarah, Berrien-Elliott, Melissa M., Westervelt, Peter, Verneris, Michael R., Wagner, John E., Weisdorf, Daniel J., Blazar, Bruce R., Ustun, Celalettin, DeFor, Todd E., Vivek, Sithara, Peck, Lindsey, DiPersio, John F., Cashen, Amanda F., Kyllo, Rachel, Musiek, Amy, Schaffer, András, Anadkat, Milan J., Rosman, Ilana, Miller, Daniel, Egan, Jack O., Jeng, Emily K., Rock, Amy, Wong, Hing C., Fehniger, Todd A., and Miller, Jeffrey S.

Published
2018
Full Text
View/download PDF

31. What Students and Faculty Should Know about Professional Licensure

Author

Wagner, John E., Parrish, William R., and Bullard, Lisa G.

Abstract

Most chemical engineering (ChE) students know very little about professional licensure and the Fundamentals of Engineering (FE) exam. Many of those who know think that licensure is something civil engineers have to get but nothing they (as chemical engineers) have to bother with. In fact, licensure is something all ChE students should be thinking about in their senior year. This article presents a hypothetical dialogue the authors believe chemical engineering educators might consider sharing with their students.

Published
2019

33. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT

Author

Dietz, Andrew C., Savage, Sharon A., Vlachos, Adrianna, Mehta, Parinda A., Bresters, Dorine, Tolar, Jakub, Bonfim, Carmem, Dalle, Jean Hugues, de la Fuente, Josu, Skinner, Roderick, Boulad, Farid, Duncan, Christine N., Baker, K. Scott, Pulsipher, Michael A., Lipton, Jeffrey M., Wagner, John E., and Alter, Blanche P.

Published
2017
Full Text
View/download PDF

36. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation

Author

Dietz, Andrew C., Mehta, Parinda A., Vlachos, Adrianna, Savage, Sharon A., Bresters, Dorine, Tolar, Jakub, Boulad, Farid, Dalle, Jean Hugues, Bonfim, Carmem, de la Fuente, Josu, Duncan, Christine N., Baker, K. Scott, Pulsipher, Michael A., Lipton, Jeffrey M., Wagner, John E., and Alter, Blanche P.

Published
2017
Full Text
View/download PDF

38. Optimization of cGMP purification and expansion of umbilical cord blood–derived T-regulatory cells in support of first-in-human clinical trials

Author

McKenna, David H., Jr., Sumstad, Darin, Kadidlo, Diane M., Batdorf, Bjorn, Lord, Colin J., Merkel, Sarah C., Koellner, Christine M., Curtsinger, Julie M., June, Carl H., Riley, James L., Levine, Bruce L., Miller, Jeffrey S., Brunstein, Claudio G., Wagner, John E., Blazar, Bruce R., and Hippen, Keli L.

Published
2017
Full Text
View/download PDF

39. Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen–Matched Grafts

Author

Brunstein, Claudio G., Cutler, Corey S., DeFor, Todd E., Kim, Haesook, Bejanyan, Nelli, Garfall, Alfred, Verneris, Michael R., Chen, Yi-Bin, Warlick, Erica D., Spitzer, Thomas, Miller, Jeffrey S., Antin, Joseph H., Weisdorf, Daniel J., Soiffer, Robert, Wagner, John E., and Ballen, Karen K.

Published
2017
Full Text
View/download PDF

44. Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation

Author

El Jurdi, Najla, Rogosheske, John, DeFor, Todd, Bejanyan, Nelli, Arora, Mukta, Bachanova, Veronika, Betts, Brian, He, Fiona, Holtan, Shernan, Janakiram, Murali, Larson, Samantha, Maakaron, Joseph, Rashidi, Armin, Warlick, Erica, Wagner, John E., Young, Jo-Anne H., Weisdorf, Daniel, and Brunstein, Claudio G.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results